Cullinan Therapeutics Autoimmune Disease Strategy 2024

Cullinan Therapeutics presented its autoimmune disease strategy and clinical development pipeline as of April 2024. The presentation outlines the company's research priorities, product candidates including CLN-978, and commercialization plans for treating autoimmune conditions. Leadership discussed regulatory pathways, competitive positioning, and strategic collaborations including partnerships with Taiho Pharmaceutical.